60-56-0 Category:
  • #LGM Pharma is a Methimazole CAS# 60-56-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 60-56-0
  • AHFC code: 08:36.1
  • Synonyms: Mercaptazole Mercasolyl Mercazole Mercazolyl Merkazolil Metazolo Methamazole Methiamazole Methimazol Metothyrin Metothyrine Thiamazol Thiamazole Thimazole Thymidazol Thymidazole
  • ATC Code: H03BB02
  • Chemical Formula: C22H30O5
  • Molecular Weight: 114.169
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00763 (APRD00002)
  • PubChem: 1349907
  • IUPAC: 1-methyl-2,3-dihydro-1H-imidazole-2-thione

Additional Details

For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
Used in the treatment of hyperthyroidism or an overactive thyroid gland, methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. It may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy.
Mode of Action:
Methimazole binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. So methimazole effectively inhibits the production of new thyroid hormones.
Primarily hepatic. Metabolized rapidly, requiring frequent administration.
Oral LD50 in rats is 2250 mg/kg. Symptoms of overdose include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancy-topenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials